Anemia Measures
ESA use any use (%) by type (% Epo, % darbepoetin) by route (% intravenous, % subcutaneous)
ESA dose Mean and categories (<5,000, 5,000–<10,000, 10,000–<25,000, 25,000–<50,000, ≥50,000 U/wk), overall and by type
Hemoglobin Mean and categories (<10, 10–<11, 11–<12, ≥12 g/dL)
Iron use any intravenous use (%) by type of intravenous preparation (%) by route (% intravenous, % oral)
IV iron dose Mean and categories (<250, 250–<500, ≥500 mg/mo)
Serum ferritin Mean and categories (<200, 200–<500, 500–<800, ≥800 ng/mL)
Serum TSAT Mean and categories (<20, 20–<35, 35–<50, ≥50%)
Mineral and Bone Disorder Measures
Serum calcium, total Mean and categories (<8.4, 8.4–9.5, 9.6–10.2; >10.2 mg/dL)
Serum calcium, albumin-corrected Mean and categories (<8.4, 8.4–9.5, 9.6–10.2; >10.2 mg/dL)
Serum phosphorus Mean and categories (<2.5, 2.5–4.5, 4.6–5.5, 5.6–7.0, >7.0 mg/dL)
Serum PTH Mean and categories (<150, 150–300, 301–600, >600 pg/mL)
PTH Measurement % patients with PTH measurement over prior 3 months
Phosphate binder any use (%) by type (%)
Vitamin D Analog any use (%) by route (% intravenous, % oral, % both) by type (%)
Cinacalcet any use (%)

Specifications of variables for reporting purposes are reported in the Methods section. Each item will be reported on the website for the nation overall and by facility type.

Note: Conversion factors for units: serum calcium in mg/dL to mmol/L, ×0.2495; serum phosphorus in mg/dL to mmol/L, ×0.3229; hemoglobin in g/dL to g/L, ×10; iron in μg/dL to μmol/L, ×0.179; No conversion necessary for ferritin in ng/mL and μg/L or parathyroid hormone (PTH) in pg/mL and ng/L.